Role of high glycogen in underperfused diabetic rat hearts with added norepinephrine.
The relationship between cardiac dysfunction and glycogen level and/or duration of diabetes was examined during underperfusion (2 ml/min/g heart weight) with 10(-6)M norepinephrine (NE) in isolated 1- and 6-week streptozotocin-diabetic rat (diabetes mellitus, DM) hearts and non-DM hearts. Glycogen levels in non-DM and 1- and 6-week DM hearts were 85, 120, and 206 mumol/g dry weight, respectively, in the subendocardium. About 13 min after the start of underperfusion with NE, the diastolic tension in 1-week DM hearts began to increase when the glycogen level had decreased to half; in 6-week DM hearts, glycogen decreased more markedly without greater lactate accumulation, but these glycogen levels were still higher (104 mumol/g dry weight) than those in 1-week DM hearts and the diastolic tension did not increase. About 17 min after the onset of underperfusion, the glycogen decreased to the 13-min level of 1-week DM hearts (64 mumol/g dry weight) and the diastolic tension began to increase. Until 20 min after the onset of underperfusion, the injury was less in 6-week than in 1-week DM hearts. However, after 60-min underperfusion with NE, when the glycogen level was markedly low in both groups ( < 20 mumol/g dry weight), diastolic tension was increased twice as much in 6-week DM as in 1-week DM hearts and was related to the decreased subendocardial ATP level. The results indicate that the markedly high glycogen content in diabetic hearts probably helps delay the start of the increase in left ventricular (LV) stiffness during underperfusion with NE. Ultimately, however, the degree of the injury depends on the duration, i.e., the severity, of the diabetes.
Higuchi
M
M
Department of Pharmacology, School of Medicine, University of the Ryukyus, Okinawa, Japan.
Miyagi
K
K
Nakasone
J
J
Sakanashi
M
M
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D004734:Energy Metabolism / Q000187:drug effects; D006003:Glycogen / Q000032:analysis / Q000502:physiology*; D007773:Lactates / Q000378:metabolism; D019344:Lactic Acid; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism*; D009638:Norepinephrine / Q000494:pharmacology*; D010477:Perfusion; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D016277:Ventricular Function, Left
D007773:Lactates; D019344:Lactic Acid; D013311:Streptozocin; D000255:Adenosine Triphosphate; D006003:Glycogen; D009638:Norepinephrine